They are glucagon-like peptide-1 (GLP-1) receptor agonists that reduce blood sugar and help with weight loss by mimicking the bodys endogenous GLP-1 hormone
( A - K ) Gipr fl/fl / Vehicle (n=8), Gipr fl/fl / mGIPR-Ab (n=7), Gipr Syn / / Vehicle (n=14), Gipr Syn / / mGIPR-Ab (n=14)
doi: 10.2337/dc20-1473 112 GiorginoFBenroubiMSunJ-HZimmermannAGPechtnerV
In this study, we saw disruptions were particularly pronounced among AOM users, peaking in late 2023
Patient Selection and Treatment Planning In our experience, the demographic profile of patients seeking nonsurgical treatment while undergoing weight loss with GLP-1-based therapies does not differ greatly from the wider aesthetic populationit is primarily females, mostly in midlife
Indicator #1 Unprecedented Growth: GLP-1 Products Redefine Revenue Trajectories (FIGURE 1) Since launch, GLP-1 drugs have generated a cumulative $71 billion in US revenue and they are projected to amass $400 billion more in the coming years to reach $470 billion by 2030
